Adenosine Inhibits Tissue Factor Expression by LPS-stimulated Human Monocytes: Involvement of the A3 Adenosine Receptor

Summary

Tissue Factor (TF), an integral membrane glycoprotein that initiates the extrinsic pathway of blood coagulation, is thought to play a major part in coronary acute events. Adenosine, an endogenous nucleoside produced by the degradation of intracellular adenosine triphosphate, has been shown to exert many cardioprotective effects via an inhibition of platelets and neutrophils. This study was conducted to determine whether adenosine (ADO) could modulate the expression of TF by human monocytes. We found that ADO inhibited TF antigen and activity on endotoxin-stimulated monocytes in a dose-dependent manner. The mechanism was at least pre-translational since ADO caused a change in the TF mRNA level. Using ADO receptor-specific analogs, we showed that highly selective A3 agonist N6-(3-iodobenzyl)-adenosine-5’-N’-methyluronamide (IB-MECA) inhibited LPSinduced TF activity expression more potently than A1 agonist R-phenylisopropyladenosine (R-PIA) and A2 agonist CGS 2180. Furthermore, A1/A3 antagonist, xanthine amine congener (XAC) blocked the effect of ADO whereas A2a, A2b and A1 antagonists were ineffective. In addition, we observed that ADO agonists inhibited monocyte TF expression in LPS-stimulated whole blood. The rank order of agonist potency suggested that A2 and A3 receptors might be involved (2-Cado > CGS = IB-MECA > R-PIA). This was supported by the fact that A2 and A3 antagonists reversed the action of 2-Cado. We conclude that TF inhibition by ADO on human purified monocytes involved A3 receptors.

Keywords

Tissue factor - adenosine - adenosine receptor - human monocytes

• References

• 1 Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983; 158: 1160-77.
• 2 Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibits O₂-generation, respectively. J Clin Invest 1990; 85: 1150-7.
• 3 Burkey TH, Webster RO. Adenosine inhibits fMLP-stimulated adherence and superoxide anion generation by neutrophils at early step in signal transduction. Biochim Biophys Acta 1993; 1175: 312-8.
• 4 Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SA, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 1992; 148: 2201-6.
• 5 Bullough DA, Magill MJ, Firestein GS, Mullane KM. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to cardiac myocytes. J Immunol 1995; 155: 2579-86.
• 6 Bouma MG, Jeuhomme TMMA, Boyle DL, Dentener MA, Voitenok NN, van den Wildenberg FAJM, Buurman WA. Adenosine inhibits neutrophil degranulation in activated human whole blood. J Immunol 1997; 158: 5400-8.
• 7 Wollner A, Wollner S, Smith JB. Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (CD11b/CD18) expression on FMLPs-timulated neutrophils. Am J Respir Cell Mol Biol 1993; 09: 179-85.
• 8 Bouma MG, Stad RK, van den Wildenberg FAJM, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994; 153: 4159-68.
• 9 Le Moine O, Stordeur P, Shandené L, Marchant A, de Groote D, Goldman M, Devière J. Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996; 156: 4408-24.
• 10 Deguchi H, Takeya H, Urano H, Gabazza EC, Zhou H, Suzuki K. Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 1998; 91: 57-61.
• 11 Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995; 35: 581-606.
• 12 Broussas M, Cornillet-Lefèbvre P, Potron G, Nguyên P. Inhibition of f-MLP triggered respiratory burst of human monocytes by adenosine: involvement of A3 adenosine receptor. J Leukoc Biol 1999; 66: 495-501.
• 13 Nguyên P, Broussas M, Cornillet-Lefèbvre P, Potron G. Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukapheresis and elutriation. Response of nonadherent cells to lipopolysaccharide. Transfusion 1999; 39: 975-82.
• 14 Amirkhosravi A, Alexander M, May K, Francis DA, Warnes G, Biggerstaff J, Francis JL. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost 1996; 75: 87-95.
• 15 Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-a expression by adenosine: a role for A3 adenosine receptor. J Immunol 1996; 156: 3435-42.
• 16 Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal 1999; 11: 1-14.
• 17 Polack B, Pernod G, Barro C, Doussiere J. Role of oxygen radicals in tissue factor induction by endotoxin in blood monocytes. Haemostasis 1997; 27: 193-200.
• 18 Jin X, Sheperd RK, Duling BR, Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest 1997; 100: 2849-57.
• 19 German DC, Kredich NM, Bjornsson TD. Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther 1989; 45: 80-4.
• 20 Olafsson B, Forman M, Puett D. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no reflow phenomenon. Circulation 1987; 76: 1135-45.
• 21 Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-9.